Navigation Links
Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
Date:8/5/2013

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO Mark L. Baum will present at the Southern California Investor Conference on August 8, 2013 at the Island Hotel in Newport Beach, CA. The Imprimis presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT. in Room 2.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the commercial development of drug formulations utilizing the FDA 505(b)(2) drug development pathway. Through its exclusive strategic relationship with the largest compounding pharmacy organization in North America as well as through a growing network of commercial development relationships with pharmacists and physicians across the United States, Imprimis expects to use proprietary drug delivery technologies, proven drug formulations and proprietary market data to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need.  Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes its patented Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/

Contact:
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
3. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
4. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
5. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
6. Imprimis Announces Key Leadership Appointments
7. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
8. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
9. Imprimis to Begin New Study of Its Topical Analgesic Drug
10. Imprimis Names Two Experts To Its Science And Regulatory Board
11. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... July 28, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... developer, manufacturer and marketer of orthopedic implants in China, today ... financial results on August 16, 2011, before the market opens. ... a.m. ET on August 16, 2011 to discuss second quarter ...
... Soligenix, Inc. (Soligenix or the Company) (OTC BB: ... amendment of its North American licensing partnership with Sigma ... development and commercialization of orBec® (oral beclomethasone dipropionate or ... part of the amended agreement, Sigma - Tau has ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 3Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 4Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 5Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 6Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 7Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 8
(Date:4/23/2014)... computer program could help doctors predict which patients might ... , The program, which assesses brain scans using ... security and passport control, has been developed by researchers ... funded by the Wellcome Trust, which used the software ... , Stroke affects over 15 million people each ...
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... for-profit and non-profit organizations in Washington will receive ... Concept grants to accelerate maturation of promising health-related ... Sciences Discovery Fund (LSDF) announced today. Also announced ... the Washington Biotechnology & Biomedical Association (WBBA) to ... next generation of entrepreneurs and help early-stage companies ...
(Date:4/23/2014)... and physicians concerned about an increase in adolescents, marijuana ... a sigh of relief. According to a new study ... of data from states with and without medical marijuana ... use among adolescents. The study is published online in ... Health . , "Any time a state considers ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
... 'allergies' are the ones that claim millions of victims ... million people annually. While many ailments can be accounted ... deficiency of essential nutritive component like Vitamins, allergies are ... substance, one that does not bother other people. ...
... are reporting promising results from a study of a ... drug fotemustine, when delivered intravenously every three weeks, was ... // ,The drug is one of a group of ... and have since been shown to help shrink solid ...
... or after hitting the squash court might be a waste ... soreness, say researchers. Warning up and cooling down by stretching ... into painful spasm. The spasm theory turned out to be ... the “many superstitions about how to prevent injury and improve ...
... showing that calcium channel blockers are more effective at ... group of 1,800 patients were assigned to either lacidipine,// ... are used to treat high blood pressure, but act ... at which calcium flows into cells and so interferes ...
... a combined study by researchers from Ireland, Boston and the ... to reduced death rates Cleaning up the air really can ... research on a 1990 ban on coal in Dublin. They ... after the ban was implemented. After the ban, the amount ...
... All around the United States, researchers at 24 medical centers ... of macular degeneration before it progresses. There are two forms ... upto75 percent of all cases and is characterized by the ... known as drusen. People with dry macular degeneration have a ...
Cached Medicine News:Health News:Allergies: A major health problem 2
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
These backbiters enable simple access to the anterior horn of the meniscus....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: